LB PHARMACEUTICALS INC (LBRX) Form 8-K — Jun 10, 2026
LB Pharmaceuticals Inc (LBRX) announced that Anna Eramo, M.D., will resign as Chief Medical Officer effective June 15, 2026, for personal reasons. She will transition to a full-time advisory role through September 15, 2026, to ensure an orderly handover of clinical operations. The company stated that Dr. Eramo’s departure is not related to its clinical program operations and does not expect a material impact on clinical development activities or milestones.
Key figures
- Severance salary end
- 2027-06-15
- Consulting period end
- 2026-09-15
- Unvested options vesting
- 66143
Price after filing
1 day: 0.0%7 days: +5.8%30 days: +18.8%
Close on the filing date to close N calendar days later (from $28.39). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.